Kurs
-0,46%
Likviditet
0,26 MNOK
Kalender
Tid* | ||
2026-02-12 | 07:30 | Bokslutskommuniké 2025 |
2025-11-06 | 07:00 | Kvartalsrapport 2025-Q3 |
2025-08-21 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-05-08 | 07:00 | Kvartalsrapport 2025-Q1 |
2025-04-24 | N/A | X-dag ordinarie utdelning ULTI 0.00 NOK |
2025-04-23 | N/A | Årsstämma |
2025-01-31 | - | Bokslutskommuniké 2024 |
2025-01-09 | - | Extra Bolagsstämma 2025 |
2024-11-06 | - | Kvartalsrapport 2024-Q3 |
2024-08-21 | - | Kvartalsrapport 2024-Q2 |
2024-05-07 | - | Kvartalsrapport 2024-Q1 |
2024-04-25 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
2024-04-24 | - | Årsstämma |
2024-02-14 | - | Bokslutskommuniké 2023 |
2023-11-08 | - | Kvartalsrapport 2023-Q3 |
2023-08-22 | - | Kvartalsrapport 2023-Q2 |
2023-05-10 | - | Kvartalsrapport 2023-Q1 |
2023-04-21 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
2023-04-20 | - | Årsstämma |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-08-19 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-04-21 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
2022-04-20 | - | Årsstämma |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-11 | - | Kvartalsrapport 2021-Q3 |
2021-08-20 | - | Kvartalsrapport 2021-Q2 |
2021-05-11 | - | Kvartalsrapport 2021-Q1 |
2021-04-22 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
2021-04-21 | - | Årsstämma |
2021-02-17 | - | Bokslutskommuniké 2020 |
2020-11-12 | - | Kvartalsrapport 2020-Q3 |
2020-11-11 | - | Extra Bolagsstämma 2020 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-05-14 | - | Kvartalsrapport 2020-Q1 |
2020-04-16 | - | X-dag ordinarie utdelning ULTI 0.00 NOK |
2020-04-15 | - | Årsstämma |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-14 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
Oslo, January 27, 2025: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its fourth quarter 2024 results, on Friday, January 31, 2025.
The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 09:00 CET on Friday, January 31, 2025. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast. Note that the webcast presentation has been rescheduled from February 13, 2025, due to the ongoing business combination with Zelluna Immunotherapy AS, in order to fulfill regulatory requirements associated with this process.
The report and presentation will be available on the company website from 07:00 CET the same day.
For further information, please see www.ultimovacs.com or contact:
Hans Vassgård Eid, CFO and Interim CEO, Ultimovacs ASA
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632